Evidence map›Paper›PMID 32457406›Full record

ArticleCellular & molecular immunology2021

Streamlined human antibody generation and optimization by exploiting designed immunoglobulin loci in a B cell line.

Hidetaka Seo, Hitomi Masuda, Kenjiro Asagoshi, Tomoaki Uchiki, Shigehisa Kawata, Goh Sasaki, Takashi Yabuki, Shunsuke Miyai, Naoki Takahashi, Shu-Ichi Hashimoto and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Cellular & molecular immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Avian Antibodies as Potential Therapeutic Tools.Antibodies (Basel, Switzerland) · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Hidetaka SeoDepartment of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan. hidetakaseo@bio.c.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0002-8676-8955
Hitomi MasudaResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Kenjiro AsagoshiResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Tomoaki UchikiResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Shigehisa KawataResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Goh SasakiResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Takashi YabukiResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Shunsuke MiyaiResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Naoki TakahashiResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Shu-Ichi HashimotoResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Atsushi SawadaResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.ORCID http://orcid.org/0000-0002-6081-8643
Aki TakaiwaResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Chika KoyamaResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Kanako TamaiResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Kohei KurosawaResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Ke-Yi LinResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan.
Kunihiro OhtaDepartment of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan.
Yukoh NakazakiResearch Laboratories, Chiome Bioscience Inc, Tokyo, Japan. antibody@chiome.co.jp.
Tokyo University of the Arts · JPJapan Bio Products (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) are widely utilized as therapeutic drugs for various diseases, such as cancer, autoimmune diseases, and infectious diseases. Using the avian-derived B cell line DT40, we previously developed an antibody display technology, namely, the ADLib system, which rapidly generates antigen-specific mAbs. Here, we report the development of a human version of the ADLib system and showcase the streamlined generation and optimization of functional human mAbs. Tailored libraries were first constructed by replacing endogenous immunoglobulin genes with designed human counterparts. From these libraries, clones producing full-length human IgGs against distinct antigens can be isolated, as exemplified by the selection of antagonistic mAbs. Taking advantage of avian biology, effective affinity maturation was achieved in a straightforward manner by seamless diversification of the parental clones into secondary libraries followed by single-cell sorting, quickly affording mAbs with improved affinities and functionalities. Collectively, we demonstrate that the human ADLib system could serve as an integrative platform with unique diversity for rapid de novo generation and optimization of therapeutic or diagnostic antibody leads. Furthermore, our results suggest that libraries can be constructed by introducing exogenous genes into DT40 cells, indicating that the ADLib system has the potential to be applied for the rapid and effective directed evolution and optimization of proteins in various fields beyond biomedicine.

Indexed as

Antibody FormationAmino Acid SequenceAnimalsAntibodiesAntibodies, MonoclonalAntibodies, NeutralizingBase SequenceB-LymphocytesCell LineChickensGene ConversionGene DosageGenetic VariationHumansHydroxamic AcidsPseudogenesAntibodiesAntibodies, MonoclonalAntibodies, NeutralizingHydroxamic Acidstrichostatin ATumor Necrosis Factor-alphaVascular Endothelial Growth Factor Aantibody engineeringantibody therapeuticsdrug discoveryhomologous recombinationImmunoglobulin rearrangements

Identifiers

PMID32457406
PMCPMC8166883
OpenAlexW3032060771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.